257 related articles for article (PubMed ID: 14563644)
1. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.
Landais E; Saulquin X; Scotet E; Trautmann L; Peyrat MA; Yates JL; Kwok WW; Bonneville M; Houssaint E
Blood; 2004 Feb; 103(4):1408-16. PubMed ID: 14563644
[TBL] [Abstract][Full Text] [Related]
2. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen.
Landais E; Saulquin X; Bonneville M; Houssaint E
J Immunol; 2005 Dec; 175(12):7939-46. PubMed ID: 16339529
[TBL] [Abstract][Full Text] [Related]
3. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
4. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
5. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G; Münz C
J Virol; 2003 Nov; 77(22):12088-104. PubMed ID: 14581546
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.
Long HM; Haigh TA; Gudgeon NH; Leen AM; Tsang CW; Brooks J; Landais E; Houssaint E; Lee SP; Rickinson AB; Taylor GS
J Virol; 2005 Apr; 79(8):4896-907. PubMed ID: 15795275
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.
Long HM; Leese AM; Chagoury OL; Connerty SR; Quarcoopome J; Quinn LL; Shannon-Lowe C; Rickinson AB
J Immunol; 2011 Jul; 187(1):92-101. PubMed ID: 21622860
[TBL] [Abstract][Full Text] [Related]
8. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
Adhikary D; Behrends U; Boerschmann H; Pfünder A; Burdach S; Moosmann A; Witter K; Bornkamm GW; Mautner J
PLoS One; 2007 Jul; 2(7):e583. PubMed ID: 17611619
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
10. A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.
Rajnavölgyi E; Nagy N; Thuresson B; Dosztányi Z; Simon A; Simon I; Karr RW; Ernberg I; Klein E; Falk KI
Int Immunol; 2000 Mar; 12(3):281-93. PubMed ID: 10700463
[TBL] [Abstract][Full Text] [Related]
11. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
12. Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1.
White CA; Cross SM; Kurilla MG; Kerr BM; Schmidt C; Misko IS; Khanna R; Moss DJ
Virology; 1996 May; 219(2):489-92. PubMed ID: 8638417
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
14. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
15. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.
Gudgeon NH; Taylor GS; Long HM; Haigh TA; Rickinson AB
J Virol; 2005 May; 79(9):5477-88. PubMed ID: 15827162
[TBL] [Abstract][Full Text] [Related]
16. HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals.
Ventura C; Bisceglia H; Girerd-Chambaz Y; Burdin N; Chaux P
J Clin Immunol; 2012 Dec; 32(6):1305-16. PubMed ID: 22797815
[TBL] [Abstract][Full Text] [Related]
17. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
18. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.
MacArthur GJ; Wilson AD; Birchall MA; Morgan AJ
J Virol; 2007 May; 81(9):4766-75. PubMed ID: 17314172
[TBL] [Abstract][Full Text] [Related]
19. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G
J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
